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ABSTRACT
The distribution of eprinomectin in goat milk and cheeses (cacioricotta, caciotta, caprilisco) with different ripening times
following a pour-on administration at a single dose rate (500 mg/kg of body weight) and a double dose rate (1,000 mg/kg of
body weight) to goats with naturally occurring infections of gastrointestinal nematodes was studied. Milk residues of epri-
nomectin reached a maximum of 0.55 6 0.18 mg/kg and 1.70 6 0.31 mg/kg at the single and double doses, respectively. The
drug concentrations decreased progressively until the fifth day after treatment, when they were less than the detection limit at
both dose rates. The eprinomectin levels measured in all cheese types (both treatments) were higher than those recovered in
milk at all the sampling times. In caciotta cheeses, the eprinomectin residues levels were constantly higher than other cheeses.
With the exception of cheeses made with milk the first day after treatment, eprinomectin concentrations were nearly constant
up to the fourth day then decreased by the fifth and sixth days after treatment. In all cases, at both the single and double
dosages, the maximum level of eprinomectin residues in goat milk and cheeses remained below the maximum residual level
of 20 mg/liter permitted for lactating cattle.
Few anthelmintics have been cleared for use in lactat-
ing animals where the milk is destined for human con-
sumption (5). Eprinomectin (49-[epiacetylamino]-49deoxy-
avermectin) is a member of the avermectin class of com-
pounds marketed as a pour-on endectocide for use in cattle
at a dose rate of 500 mg/kg of body weight (20, 21). It has
been found highly effective in cattle against adult and im-
mature nematodes, including the inhibited larval stages of
Ostertagia ostertagi (8, 13, 18, 21, 22, 23) and in sheep
against gastrointestinal nematodes of naturally infected an-
imals (9, 16). In addition, recent results (10) show that the
activity of eprinomectin applied topically to goats with nat-
urally occurring infection of the gastrointestinal nematodes
Teladorsagia circumcincta, Haemonchus contortus, Tricho-
strongylus colubriformis, and Oesophagostomum venulos-
um is significantly higher at the double dose rate of 1,000
mg K21g than at the single dose rate of 500 mg/kg. Epri-
nomectin is known to be subjected to minimal partitioning
into milk of lactating cattle. The resulting negligible milk
residues make its use possible in lactating dairy cattle (21).
As far as goats are concerned, the pharmacokinetic profiles
of eprinomectin have been obtained following topical (1,
12) and subcutaneous administration (15).
The aims of the present study were to investigate the
* Author for correspondence. Tel: 0039-81-459560; Fax 0039-81-458683;
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fate of eprinomectin in goat milk and to evaluate to what
extent eprinomectin levels may be present in cheeses with
different ripening times following a pour-on administration
at the single and double dose rates to pastured goats with
naturally occurring infection of gastrointestinal nematodes.
MATERIALS AND METHODS
Study animals. For the field trial, a total of 50 female Siriana
lactating goats, aged between 2 and 4 years and weighing between
40 and 50 kg, were used. The animals were kept under field con-
ditions during the entire experimental period. The pasture (60 ha)
was permanent and hilly, and the predominant forage species were
Galium spp., Cicorium spp., Dactylis glomerata, and Lolium per-
enne. No moving of animals was performed immediately before
or during the study. No supplementary feeding was given, and
water was supplied in a drainage ditch that surrounded the pasture.
The goats, according their body weight, were divided in two
treatment groups of 25 animals each. One group was treated with
an eprinomectin single dose (E1 group) the other with an epri-
nomectin double dose (E2 group). Each treatment group was
maintained on a separate but comparable pasture, thus avoiding
physical contact among goats of different treatment groups.
Treatments. The treatments were performed on 10 June
2003 (day 0). Eprinomectin (Eprinex, Merial- Italia) was given in a pour-
on administration as a 0.5% solution at the dose rate of 500 mg/
kg of body weight (1 ml/10 kg of body weight) to animals in the
E1 group and at the dose rate of 1,000 mg/kg of body weight (2
ml/10 kg of body weight) to animals in the E2 group. The dosages
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were calculated on the basis of the animal body weight on day 0.
The formulation was applied topically with a syringe along the
midline of the back from the withers to the tail head. All animals
were dry at the time of the treatments, and rain did not occur until
42 days after treatment. All treated animals were intermittently
observed for adverse reactions for 4 h after treatment and then
daily until the end of the trial. At these observation times, the
application sites were visually examined for any significant hair
and/or skin changes. Dairy goats were milked twice a day, and
the milk production measured before and throughout the trial
ranged from 500 to 1,200 ml/day.
Milk and cheese samples. Samples of milk were collected
from each animal before treatments and at 24, 48, 72, 96, 120,
and 144 h after treatment. The total daily production was collected
and kept at 48C. An aliquot was stored at 2188C until analysis.
The remaining part of the milk was processed to produce three
different kinds of cheeses named cacioricotta, caciotta, and ca-
prilisco, with ripening periods of 20, 40, and 80 days, respectively.
The summarized processing techniques of each cheese are de-
scribed herein and in the article by Rubino et al. (19). For ca-
cioricotta, raw milk was heated to 85 to 908C and then cooled to
388C, at which point a paste of kid rennet was added. On coag-
ulation, the curd was broken with a wooden stick to granules the
size of rice grains. Next, the curd was gathered on the bottom of
the vat, put into small wicker baskets, and set to dry on a tilted
wooden table. Salt was rubbed on the cheese once a day for 3
days. After 7 days, the forms were dipped into fresh water for 24
h, dried, and aged 20 days on wooden tables. The moisture content
was 59%. For caciotta, raw milk was heated to 36 to 388C and a
paste of kid rennet added. On coagulation, the curd was broken
with a wooden stick to granules the size of nuts. After this, the
techniques are similar to those described for cacioricotta, except
for the ripening time of 40 days. The moisture content of caciotta
was 30%. For caprilisco, the processing technique was similar to
that of cacioricotta and caciotta cheeses with the following dif-
ferences: the use of liquid kid rennet and the partial cooking of
the curd to 40 to 428C, the curd was broken to granules of the
size of corn kernels, and the ripening time was 80 days. The
moisture content of caprilisco was 30%. For each cheese type and
for each sampling time, 6 samples were analyzed in duplicate;
thus, the total number of samples was 126. Results are means and
standard deviations.
Analytical procedures. Water, methanol, and acetonitrile
(high-performance liquid chromatography grade) were obtained
from Carlo Erba (Milan, Italy). Trifluoracetic anhydride and N-
methylimidazole of analytical grade were purchased from Aldrich
(St. Louis, Mo.). The Solid Phase Extraction (SPE )columns were C8 cartridges Bond Elut,
500 mg (Carlo Erba).
Drug extraction and derivatization. The analytical standard
of eprinomectin was obtained from Merck and Co. (Rahaway,
N.J.). A standard stock solution of eprinomectin (1 mg/ml) was
prepared in methanol and was stored at 2208C. A working stan-
dard solution (0.2 mg/ml) was prepared from the standard stock
solution on the day of use. Milk (5 ml) and cheese (2 g) samples
were extracted with acetonitrile (15 ml) and cleaned-up by SPE
on C8 cartridges preconditioned with acetonitrile, water, and tri-
ethylamine as previously described (4). Residues were eluted with
acetonitrile. The eluate was collected in a clean test tube and evap-
orated to dryness under nitrogen at 608C.
A 225-ml portion of methylimidazole-acetonitrile (2 1 7, vol/
vol) was added to the test tube, which was vortexed for 2 min.
Successively, a similar portion (225 ml) of trifluoracetic anhy-
dride-acetonitrile (2 1 7, vol/vol) was added, and the tube was
vortexed for 1 min. Finally, a 50-ml portion of glacial acetic acid
was added, and the tube was vortexed for 1 min (11). The deriv-
atized sample extract was filtered through a 0.45 mm filter into a
vial and injected (100 ml) into the high-performance liquid chro-
matography system.
Chromatographic conditions. Milk and cheese residues of
eprinomectin were analyzed using a high-performance liquid chro-
matography system that consisted of a Jasco (Tokyo, Japan) in-
strument equipped with a ternary pump (PU-90), an autosampler
(AS-2055 PLUS), and a fluorescence detector (FP 210). The sep-
aration was performed on a stainless-steel analytical Novapack C 18 HPLC column (150
3 3.9 mm) (Waters, Massachusetts, USA.). The column temperature was maintained at 308C.
The mobile phase, which consisted of methanol plus 1% trieth-
ylamine in acetonitrile plus 1% phosphoric acid in water (61 1
30 1 9.0, vol/vol/vol), was pumped at 1 ml/min. Excitation and
emission wavelengths were 365 and 470 nm, respectively.
Method validation. A standard mixture was analyzed at 2.5,
12.5, 25, 50, and 100 mg/liter to check the linearity. These mix-
tures were obtained from a working solution of 0.2 mg/ml and
were evaporated and derivatized as described herein. A calibration
curve was constructed by plotting peak area (y) versus standard
concentration (x). Recovery was measured by comparison of the
peak areas from spiked milk with the peak areas that result from
direct injections of standards in methanol.
Five-gram portions of negative control goat milk were
weighed in 50-ml extraction tubes to determine accuracy. A 50-
ml portion of a 0.2-, 0.3-, and 0.4-mg/ml standard solution was
added to give fortification levels of 2, 3, and 4 mg/kg, respectively.
Fortified samples were extracted, cleaned, and determined as de-
scribed earlier. The precision of the method, expressed as within-
day repeatability, was determined by analyzing samples spiked
with eprinomectin standard solution. The specificity of the method
was confirmed by analysis of blank samples. No interfering peak
eluted at the same retention time of eprinomectin. The detection
limit and the limit of quantification calculated according to AOAC
International guidelines (3) criteria were 0.045 mg/liter and 0.080
mg/kg, respectively.
RESULTS AND DISCUSSION
During the study, the eprinomectin formulation (at the
dose rate of both 500 and 1,000 mg/kg of body weight) was
well tolerated by all the treated animals with no adverse
reactions to the treatments. The analytical method used to
extract, derivatize, and quantify the milk and cheese epri-
nomectin concentrations was shown to be adequate. The
regression analysis of the data obtained from the standard
solutions showed that the eprinomectin responses were lin-
ear over the range of the concentrations examined (1 to 100
mg/liter). The correlation coefficient (r2) obtained exceeded
0.99, demonstrating a good linearity. The overall eprino-
mectin recoveries were 88.2 and 89.4% for milk and
cheese, respectively. Intra-assay variations ranged from 9.0
(milk) to 10.0% (cheese).
Time concentration profiles after pour-on eprinomectin
administrations of 500 and 1,000 mg/kg of body weight in
goat milk and dairy products are shown in Figures 1
through 4. Milk residues of eprinomectin reached maxi-
mum peak levels of 0.55 6 0.18 mg/kg and 1.70 6 0.31
mg/kg after application of the dosage suggested from the
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FIGURE 1. Concentration-time profile of eprinomectin in the milk of goats following pour-on administration of the drug at 500 mg/kg
of body weight (a) and 1,000 mg/kg of body weight (b).
FIGURE 2. Concentration-time profile of eprinomectin in the cacioricotta cheese (20-day ripening period) following pour-on admin-
istration of the drug at 500 mg/kg of body weight (a) and 1,000 mg/kg of body weight (b).
manufacturer for cattle and of the double dosage, respec-
tively. The drug concentrations decreased progressively un-
til the fourth day after treatment, when they were less than
the detection limit at both dose rates (Fig. 1).
The eprinomectin levels measured in all cheese types
(both treatments) were higher than those recovered in milk
at all sampling times. The concentrations of drug residues
were similar in all cheeses made with milk sampled on the
first day after treatment. Concentrations ranged from 9.71
6 0.9 to 10.9 6 1.0 ng/g at the dose rate of 500 mg/kg
and 19.21 6 10.8 to 20.75 6 1.6 mng/g at the dose rate of
1,000 mg/kg for cacioricotta (20-day ripening period) and
caciotta (40-day ripening period), respectively. These con-
centrations were the eprinomectin maximum peak levels.
From the second day on, in cacioricotta and caprilisco the
residue concentrations decreased progressively to 2.65 6
0.4 and 0.53 6 0.07 ng/g for the single dose and 6.37 6
0.9 and 1.2 6 0.3 ng/g for the double dose, respectively
(Figs. 2 and 4). In caciotta cheeses, the eprinomectin resi-
due levels were consistently higher than those in the other
cheeses, and, in both doses, they were constant up to the
fourth day and then decreased on the fifth and sixth days
following treatment (Fig. 3).
Previous studies have reported the pharmacokinetics of
eprinomectin in dairy cattle (2) and in lactating and non-
lactating goats (1, 12). Eprinomectin concentrations detect-
ed in milk following a pour-on administration at the lower
dose were different from those observed in dairy cattle (2)
but similar to those obtained in buffalo (unpublished data)
and goats (12). In bovine milk, the eprinomectin concen-
tration was 0.89 6 0.4 ng/ml at the first sampling period,
and the maximum concentration was 5.14 6 2.5 ng/ml. In
the present experiment, the eprinomectin peak concentra-
tion was 10-fold lower (0.55 ng/ml), and residues were not
detected after day 4 after treatment.
The residues detected after administration of eprino-
mectin at the dose rate of 1,000 mg/kg of body weight were
similar to those reported by Dupuy et al. (12) following
administration of the same pour-on dose. The milk parti-
tioning process was controlled by several factors, including
physicochemical properties of the drug, membrane inter-
actions, and animal species.
In lactating animals, probably due to decrease of body
fat during the lactation (14), the drug is eliminated more
rapidly. Previous studies have shown that, in lactating goats
at a dose of 0.5 mg/kg of body weight, the mean residence
time, a parameter that integrates all the steps of the drug
fate in the body, was lower (2.6 days) than in lactating cows
(3.99 days) (1, 12), thus affecting drug efficacy.
Eprinomectin residues in cheeses seem to show a dif-
ferent behavior in relation to many factors. As observed by
other authors, this compound, because of its lipid solubility,
increases with the decrease of the water content. Studies
performed in buffalo and cow’s milk (6) show that epri-
nomectin residues are found primarily in the curd and the
concentration factor is inversely related to the manufactur-
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FIGURE 3. Concentration-time profile of eprinomectin in the caciotta cheese (40-day ripening period) following pour-on administration
of the drug at 500 mg/kg of body weight (a) and 1,000 mg/kg of body weight (b).
FIGURE 4. Concentration-time profile of eprinomectin in the caprilisco cheese (80-day ripening period) following pour-on administra-
tion of the drug at 500 mg/kg of body weight (a) and 1,000 mg/kg of body weight (b).
ing yield. That is the reason for higher concentrations in
cheeses than milk. In cheeses made from milk sampled after
6 days after treatment with eprinomectin, concentrations
were nondetectable at both doses used.
The data obtained in this study show that in caciori-
cotta and caciotta cheeses, with the exception of the first
day after treatment, eprinomectin concentrations increase as
the activity water and the yield decrease. In contrast, the
eprinomectin levels in caprilisco, the cheese with the lon-
gest aging time and with a manufacturing yield of 11%,
were similar or lower than the other two types of cheeses.
A possible explanation for this observation could be the
long ripening time (almost 80 days) during which eprino-
mectin may have undergone a degradation process.
From a parasitological point of view, recent results of
a field trial conducted on the same goats of the present
study demonstrated that the activity of eprinomectin applied
topically to goats with naturally occurring infection of T.
circumcincta, H. contortus, T. colubriformis, and O. venu-
losum was significantly higher at the dose rate of 1,000 mg/
kg of body weight than at the dose rate of 500 mg/kg of
body weight (10). In fact, 1 week after the treatment, the
control group goats had a doubling in egg counts, which
remained unchanged during the trial, whereas the single
dose group had lowered egg counts by 90% and the double
dose by 99%. These results are similar to those obtained
by Chartier et al. (5) in goats experimentally infected by
gastrointestinal nematodes.
The findings of the present study show that the use of
eprinomectin at the dose rate of 1,000 mg/kg of body
weight, the dose with the higher antiparasitic activity, did
not pose a residue problem for goat milk and dairy products
whatever their ripening time. In fact, the peak levels of the
milk and cheeses after administration of eprinomectin at
this dosage were always below the maximum residual level
of 20 mg/liter fixed by European Union (EU) for bovine milk (7). For this
reason and because of improved efficacy, a double dose of
eprinomectin for lactating goats is recommended. This
would also be of great interest to dairy goat farmers, since
the use of anthelmintics at dosages lower than those re-
quired for high efficacy may cause a build-up of anthel-
mintic resistance (10).
In conclusion, the findings of the present study dem-
onstrate that there is no hazard arising from ingestion of
milk or cheeses from goats treated with eprinomectin. This
has important implications in terms of public health and
trade of goat milk and milk products, considering the in-
creasing of human consumption of goat milk and cheeses
and the fact that goat milk has biochemical properties the-
oretically favoring its nutritional value for humans (17).
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